American Journal of Clinical Dermatology最新文献

{"title":"Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies","authors":"Maryanne Senna,&nbsp;Jennifer Soung,&nbsp;Ignasi Figueras,&nbsp;Brett King,&nbsp;Misaki Kinoshita-Ise,&nbsp;Sameh Hanna,&nbsp;Wenyu Wu,&nbsp;Dalia Wajsbrot,&nbsp;Deborah Woodworth,&nbsp;Robert Wolk,&nbsp;Alanna Chaudhry,&nbsp;Alexandre Lejeune,&nbsp;Helen Tran","doi":"10.1007/s40257-026-01029-y","DOIUrl":"10.1007/s40257-026-01029-y","url":null,"abstract":"<div><h3>Background/objective</h3><p>Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients aged ≥ 12 years with alopecia areata (AA) in the ALLEGRO phase 2b/3 study and initial extension up to month 24 in the ALLEGRO-LT study. We aimed to evaluate the efficacy of ritlecitinib up to 3 years in patients with AA from the ALLEGRO phase 2b/3 and ongoing phase 3, open-label ALLEGRO-LT studies.</p><h3>Methods</h3><p>Patients aged ≥ 12 years with AA and ≥ 50% scalp hair loss who received daily ritlecitinib 50 mg in ALLEGRO-2b/3 and rolled over to ALLEGRO-LT (continued 50 mg) were included. Observed and last observation carried forward (LOCF) data are reported based on the data cutoff (25 June 2024). Variables associated with treatment response were assessed using multivariable logistic regression.</p><h3>Results</h3><p>A total of 191 patients were included. At 3 years, 65.1% (observed) and 47.1% (LOCF) of patients had Severity of Alopecia Tool (SALT) score ≤ 20. Among patients with SALT score ≤ 20 at 1 year, most (88.3–89.6%) maintained this response at 3 years. SALT score ≤ 10 response rates at 3 years were 52.3% (observed) and 36.7% (LOCF). At 3 years, 31.2% (observed) and 22.5% (LOCF) of patients achieved SALT score 0 (complete scalp hair regrowth). Patients’ Global Impression of Change response (“moderately” or “greatly” improved) rates at 3 years were 68.4% (observed) and 55.6% (LOCF). Female sex, White race, and less extensive and shorter duration of hair loss at baseline were associated with treatment response. The safety profile was consistent with the known safety profile of ritlecitinib.</p><h3>Conclusions</h3><p>Ritlecitinib 50 mg demonstrated clinically meaningful clinician- and patient-reported efficacy up to 3 years, with no new safety signals observed. These data support the long-term use of ritlecitinib in patients aged ≥ 12 years with severe AA. [Graphical abstract and video abstract available online.].</p><h3>Clinical Trial Registration</h3><p>NCT03732807, NCT04006457, NCT04517864, NCT02974868.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 5","pages":"1091 - 1105"},"PeriodicalIF":11.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01029-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147589476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!","authors":"Luca Rapparini,&nbsp;Timila Assia Touhouche,&nbsp;Davide Fattore,&nbsp;Azael Freites-Martinez,&nbsp;Pauline Hirtz,&nbsp;Zoe Apalla,&nbsp;Emmanuelle Vigarios,&nbsp;Delphine Maret,&nbsp;Michela Starace,&nbsp;Vincent Sibaud","doi":"10.1007/s40257-026-01027-0","DOIUrl":"10.1007/s40257-026-01027-0","url":null,"abstract":"<div><p>The increasing efficacy of oncological therapies has led to a rapidly growing population of cancer survivors, shifting clinical attention from acute treatment-related toxicities to long-term and late sequelae. Among these, dermatological sequelae represent some of the most visible and persistent consequences of cancer treatments and may significantly impair quality of life. Persistent alopecia, nail disorders, pigmentary alterations, chronic radiation-induced skin changes, scarring, vascular abnormalities, mucosal alterations, and secondary skin cancers may develop or persist long after treatment completion, acting as constant reminders of the cancer experience. These conditions are not only cosmetic; they may be associated with functional limitations, psychological distress, and altered body image, particularly in patients treated during childhood or adolescence. While the role of supportive oncodermatology during active cancer treatment is well established, structured dermatological care in the survivorship phase remains insufficiently developed. This narrative review provides a comprehensive overview of the main long-lasting dermatological adverse events associated with chemotherapy, radiotherapy, targeted therapies, immunotherapy, endocrine treatments, and hematopoietic stem cell transplantation. In addition, available restorative and corrective dermatological interventions are discussed, with a focus on improving long-term outcomes and patient well-being. Recognizing and managing dermatological sequelae is an essential component of modern survivorship care, and dermatologists should play a central role in multidisciplinary follow-up programs dedicated to cancer survivors.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"515 - 535"},"PeriodicalIF":8.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01027-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147589481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis","authors":"Amy S. Paller,&nbsp;Eric L. Simpson,&nbsp;Elaine C. Siegfried,&nbsp;Michael J. Cork,&nbsp;Peter D. Arkwright,&nbsp;Andreas Pinter,&nbsp;Mette Deleuran,&nbsp;H. Chih-ho Hong,&nbsp;Yonghao Ma,&nbsp;Ashish Bansal,&nbsp;Ariane Dubost-Brama,&nbsp;Tien V. Nguyen","doi":"10.1007/s40257-026-01018-1","DOIUrl":"10.1007/s40257-026-01018-1","url":null,"abstract":"<div><h3>Background</h3><p>Atopic dermatitis (AD) is a chronic inflammatory disease with a high clinical burden and risk of persistence in pediatric patients.</p><h3>Objective</h3><p>To assess safety and efficacy of treatment with dupilumab for up to 2 years in infants and young children with AD.</p><h3>Methods</h3><p>Patients aged 6 months to 5 years who had previously participated in parent studies LIBERTY AD PRESCHOOL Part A or B (NCT03346434), with moderate-to-severe AD at parent study baseline, were enrolled in the ongoing LIBERTY AD PED open-label extension (OLE) study (NCT02612454). Patients initially received weight-based dupilumab (3 or 6 mg/kg once a week); following protocol amendment, patients were switched to a weight-tiered dose every 4 weeks (200 mg for patients weighing 5 to &lt; 15kg; 300 mg for patients weighing 15 to &lt; 30kg). The use of concomitant medications (topical corticosteroids, antihistamines, and topical calcineurin inhibitors) was permitted without restriction, but patients were not permitted to use systemic medication for AD except as rescue treatment. Analyses were descriptive, with no formal statistical hypothesis.</p><h3>Results</h3><p>This analysis included 180 patients, of whom 106 completed the week 104 visit. A total of 87.8% patients experienced treatment-emergent adverse events (TEAEs; 24.4% mild, 52.2% moderate, 11.1% severe). One serious, drug-related TEAE (pinworm infection) did not lead to treatment discontinuation and resolved over time. One drug-related event of severe urticaria led to permanent treatment discontinuation but was not considered serious and resolved over time. By week 104, 92.1% patients achieved a 75% reduction in Eczema Area and Severity Index from parent study baseline, and the mean reduction in body surface area affected by AD was 49.0% from parent study baseline.</p><h3>Conclusions</h3><p>In this OLE study, treatment with dupilumab for up to 2 years in infants and young children with AD demonstrated sustained efficacy with a safety profile consistent with prior studies, supporting its long-term continuous use in pediatric patients.</p><h3>Clinical Trial Registration</h3><p>ClinicalTrials.gov Identifier: NCT02612454</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture><span>The alternative text for this image may have been generated using AI.</span></div></div></figure></div></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"611 - 620"},"PeriodicalIF":8.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01018-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychocutaneous Disorders in Pediatric and Adolescent Populations: A Narrative Review","authors":"Isabella J. Tan,&nbsp;Alexis Mitelman,&nbsp;Mohammad Jafferany","doi":"10.1007/s40257-026-01026-1","DOIUrl":"10.1007/s40257-026-01026-1","url":null,"abstract":"<div><p>Psychocutaneous disorders (PCDs) in children and adolescents lie at the intersection of dermatology and psychiatry and include primary psychiatric conditions with cutaneous manifestations, dermatologic diseases with psychiatric sequelae, and functional or overlap syndromes. Despite substantial psychosocial burden and chronic morbidity, pediatric PCDs remain under-recognized and inconsistently managed. We conducted a narrative review of PubMed, Embase, PsycINFO, Scopus, and Web of Science (2000–2025), including epidemiologic studies, clinical trials, meta-analyses, and consensus statements addressing prevalence, risk factors, diagnostic tools, and management strategies in pediatric psychodermatology. Available data suggest that 20–30% of youth with chronic skin disease have comorbid psychiatric conditions; trichotillomania and excoriation disorder affect approximately 1–5% of children, and adolescents with acne have a two- to three-fold increased risk of depression. Diagnosis is frequently delayed due to overlapping clinical presentations, limited clinician training, and inconsistent use of validated screening instruments, many of which are better studied in older adolescents than younger children. Behavioral interventions remain first-line for most pediatric PCDs, with pharmacologic therapy reserved for moderate-to-severe or refractory cases; optimized dermatologic management may mitigate secondary psychiatric distress. Early recognition through structured screening, developmentally informed assessment, and attention to family and psychosocial context is needed to improve outcomes. Key gaps include limited pediatric-specific epidemiologic data, insufficient validation of assessment tools in younger populations, and a lack of longitudinal treatment studies, highlighting the need for targeted research to inform care.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"493 - 502"},"PeriodicalIF":8.8,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01026-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147519631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study","authors":"Michela Starace,&nbsp;Luca Rapparini,&nbsp;Francesca Pampaloni,&nbsp;Stephano Cedirian,&nbsp;Federico Quadrelli,&nbsp;Francesca Bruni,&nbsp;Ginevra Martelli,&nbsp;Giampiero Girolomoni,&nbsp;Francesco Bellinato,&nbsp;Paolo Gisondi,&nbsp;Giuseppe Gallo,&nbsp;Simone Ribero,&nbsp;Michela Ortoncelli,&nbsp;Pietro Quaglino,&nbsp;Luigi Gargiulo,&nbsp;Carlo Vignoli,&nbsp;Alessandra Narcisi,&nbsp;Francesca Ambrogio,&nbsp;Caterina Foti,&nbsp;Raffaele Dante Caposiena Caro,&nbsp;Iris Zalaudek,&nbsp;Angelo Valerio Marzano,&nbsp;Andrea Sechi,&nbsp;Mauro Barbareschi,&nbsp;Luca Valtellini,&nbsp;Silvia Mariel Ferrucci,&nbsp;Laura Diluvio,&nbsp;Enrico Matteini,&nbsp;Luca Bianchi,&nbsp;Mariateresa Cantelli,&nbsp;Paola Nappa,&nbsp;Carolina D’Elia,&nbsp;Valeria Boccaletti,&nbsp;Carola Romanò,&nbsp;Elisabetta Fulgione,&nbsp;Anna Balato,&nbsp;Giuseppe Argenziano,&nbsp;Emanuele Trovato,&nbsp;Elisa Cinotti,&nbsp;Pietro Rubegni,&nbsp;Federica Dall’Oglio,&nbsp;Francesco Lacarrubba,&nbsp;Giuseppe Micali,&nbsp;Elena Pezzolo,&nbsp;Francesca Caroppo,&nbsp;Anna Belloni Fortina,&nbsp;Giacomo Caldarola,&nbsp;Ketty Peris,&nbsp;Lorenzo Maria Pinto,&nbsp;Calogero Pagliarello,&nbsp;Riccardo Balestri,&nbsp;Carlo Tomasini,&nbsp;Stefania Barruscotti,&nbsp;Laura Atzori,&nbsp;Silvia Sanna,&nbsp;Lorenzo Ala,&nbsp;Giulio Bortone,&nbsp;Giovanni Pellacani,&nbsp;Alfredo Rossi,&nbsp;Serena Lembo,&nbsp;Annunziata Raimondo,&nbsp;Flavia Manzo Margiotta,&nbsp;Valentina Dini,&nbsp;Marco Romanelli,&nbsp;Andrea Megna,&nbsp;Francesca Prignano,&nbsp;Gianmarco Silvi,&nbsp;Oriana Simonetti,&nbsp;Edoardo De Simoni,&nbsp;Michela Magnano,&nbsp;Natale Schettini,&nbsp;⁠⁠Alessandro Borghi,&nbsp;Francesca Satolli,&nbsp;Maria Beatrice de Felici del Giudice,&nbsp;Franco Rongioletti,&nbsp;Stefania Guida,&nbsp;Gianmarco Diego Bigotto,&nbsp;Cesare Filippeschi,&nbsp;Teresa Oranges,&nbsp;Greta Tronconi,&nbsp;Bianca Maria Piraccini","doi":"10.1007/s40257-026-01022-5","DOIUrl":"10.1007/s40257-026-01022-5","url":null,"abstract":"<div><h3>Background</h3><p>Ritlecitinib, an oral selective inhibitor of Janus kinase 3 and the TEC family of kinases, has recently been approved for the treatment of severe alopecia areata, but real-world data are still limited.</p><h3>Objective</h3><p>The aim was to evaluate the effectiveness and tolerability of ritlecitinib 50 mg/day after 24 weeks in patients with severe alopecia areata in clinical practice.</p><h3>Methods</h3><p>We performed an Italian observational, retrospective, multicentre study with 24 weeks of follow-up. Patients ≥ 12 years of age with severe alopecia areata (Severity of Alopecia Tool [SALT] ≥ 50) and a disease duration ≥ 6 months who were candidates for systemic therapy were enrolled. Ritlecitinib 50 mg/day was administered according to national guidelines. The primary endpoint was to evaluate the achievement of SALT ≤ 20 at week 24. Secondary endpoints included achievement of SALT ≤ 10; mean change in SALT; trichoscopic improvement; quality of life; psychological impact; efficacy in eyebrows, eyelashes, and nails; and safety profile.</p><h3>Results</h3><p>A total of 102 patients were included. At week 24, 40.2% of patients achieved SALT ≤ 20, with a greater response in adolescents (48.6%) than in adults (21.9%). The mean SALT score decreased from 86.2 ± 18.5 to 40.8 ± 37.1. Significant improvements were observed in trichoscopic signs and quality of life. The treatment was also effective on eyebrows, eyelashes, and nails. Adverse events were mild (e.g., acne, headache). Ritlecitinib had to be discontinued in only one case of severe anaemia.</p><h3>Conclusions</h3><p>In this multicentre real-world study, ritlecitinib 50 mg/day was an effective and well-tolerated treatment option for severe alopecia areata.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"621 - 630"},"PeriodicalIF":8.8,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01022-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposome Risk Factors for Vitiligo: A Systematic Evidence Review","authors":"Jaime Piquero-Casals,&nbsp;Clémence Bertold,&nbsp;Agustín Alomar,&nbsp;Daniel Morgado-Carrasco,&nbsp;Yolanda Gilaberte,&nbsp;José Luis López-Estebaranz,&nbsp;Antonio Massa,&nbsp;Caio Silva de Castro,&nbsp;Giovanni Leone,&nbsp;Henry W. Lim,&nbsp;Jean Krutmann,&nbsp;Khaled Ezzedine,&nbsp;Thierry Passeron","doi":"10.1007/s40257-026-01012-7","DOIUrl":"10.1007/s40257-026-01012-7","url":null,"abstract":"<div><h3>Background</h3><p>Vitiligo is a multi-factorial autoimmune skin disorder often triggered by environmental exposures. Although the exposome has gained attention, no systematic review has fully assessed its role in vitiligo.</p><h3>Objective</h3><p>We aimed to evaluate evidence linking exposomal factors to vitiligo onset and progression, focusing on quantifiable associations and study quality.</p><h3>Methods</h3><p>A systematic search of PubMed and Embase (inception to 25 August, 2024) followed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 2020 guidelines and was registered in PROSPERO (CRD42024529828). Eligible studies reported associations between environmental exposures and vitiligo onset, flares, or progression. Observational studies, case series, clinical trials, and pharmacovigilance reports were included. Findings were synthesized narratively.</p><h3>Results</h3><p>Of 8377 records, 496 studies met inclusion criteria. Drug-associated vitiligo, particularly from immune checkpoint inhibitors, was the most robustly supported association (7–25% in patients with melanoma). Phenol-based chemicals were consistently linked to melanocyte toxicity. Coronavirus disease 2019 infection modestly increased risk (hazard ratio ≈ 1.11), while vaccination did not. Other factors such as stress (<i>n</i> = 113), trauma, sunburn, smoking, diet, and sleep were frequently cited but supported by lower-level evidence. Study heterogeneity, a lack of standardized outcomes, and the predominance of observational designs limited meta-analysis and causal inference.</p><h3>Conclusions</h3><p>These findings highlight the environmental triggers of vitiligo onset and progression. Drugs, chemicals, and infections are key triggers; lifestyle factors require further study.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"465 - 478"},"PeriodicalIF":8.8,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study","authors":"Kanokvalai Kulthanan,&nbsp;Jonathan A. Bernstein,&nbsp;Michael Rudenko,&nbsp;Pascale Salameh,&nbsp;Chulaluk Komoltri,&nbsp;Zainab Abdul Hameed,&nbsp;Esra Adışen,&nbsp;Salma Al Abri,&nbsp;Mona Al-Ahmad,&nbsp;Bushra Al Hinai,&nbsp;Anastasiia Allenova,&nbsp;Saad Alshareef,&nbsp;Nattha Angkoolpakdeekul,&nbsp;Rand Arnaout,&nbsp;Joanna Bartosińska,&nbsp;Ivan Cherrez-Ojeda,&nbsp;Leena Chularojanamontri,&nbsp;Paulo Ricardo Criado,&nbsp;Heyam Elsaeed,&nbsp;Roberta Fachini Jardim Criado,&nbsp;Ahmed Farahat,&nbsp;Cesar Alberto Galvan Calle,&nbsp;Ana Maria Giménez-Arnau,&nbsp;Kiran Godse,&nbsp;Maia Gotua,&nbsp;Mehmet Gülengül,&nbsp;Michihiro Hide,&nbsp;Naoko Inomata,&nbsp;Chang-Gyu Jung,&nbsp;Alicja Kasperska-Zając,&nbsp;Maryam Khoshkhui,&nbsp;Pavel Kolkhir,&nbsp;Dorota Krasowska,&nbsp;Jomgriditip Laomoleethorn,&nbsp;Antonina Maiorowa,&nbsp;Prynn Manuskiatti,&nbsp;Raisa Meshkova,&nbsp;Dragan Mijakoski,&nbsp;Melba Muñoz,&nbsp;Iman Nasr,&nbsp;Denise Neiva Santos de Aquino Arnoldi,&nbsp;Rabia Öztaş Kara,&nbsp;Teerapat Paringkarn,&nbsp;Juliette Pérez-Manich,&nbsp;Indrashis Podder,&nbsp;Karla Robles-Velasco,&nbsp;Isabel Rosmaninho,&nbsp;Phuwakorn Saengthong-aram,&nbsp;Giorgi Shengelidze,&nbsp;Sariya Sittiwanaruk,&nbsp;Rana Tafrishi,&nbsp;Natasa Teovska Mitrevska,&nbsp;Vesna Trajkova,&nbsp;Papapit Tuchinda,&nbsp;Noldtawat Viriyaskultorn,&nbsp;Teerapat Wannawittayapa,&nbsp;Pornjira Wattanasillawat,&nbsp;Anushka Wilson,&nbsp;Young-Min Ye,&nbsp;Anna Zalewska-Janowska,&nbsp;Marcus Maurer,&nbsp;Torsten Zuberbier","doi":"10.1007/s40257-026-01015-4","DOIUrl":"10.1007/s40257-026-01015-4","url":null,"abstract":"<div><h3>Background and Objective</h3><p>Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally.</p><h3>Methods</h3><p>The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD.</p><h3>Results</h3><p>Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease.</p><h3>Conclusions</h3><p>Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online]</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture><span>The alternative text for this image may have been generated using AI.</span></div></div></figure></div></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"631 - 645"},"PeriodicalIF":8.8,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01015-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Religious and Cultural Considerations for the Dermatologic Care of Muslim Communities: A Narrative Review of Patient-Centered Strategies","authors":"Yasser M. Almansour,&nbsp;Ferdos Abdulkader,&nbsp;Deena Abdel-Gadir,&nbsp;Sarah J. Shareef,&nbsp;Mustufa Jafry,&nbsp;Fatima Fahs,&nbsp;Tasneem F. Mohammad","doi":"10.1007/s40257-026-01020-7","DOIUrl":"10.1007/s40257-026-01020-7","url":null,"abstract":"<div><p>Muslim patients may participate in religious and cultural practices that can affect their dermatologic health and influence their preferences regarding care and treatment. In this narrative review, we explore these topics and present culturally sensitive strategies for improving patient care for Muslim communities. We performed a literature review and identified articles published between 2005 and 2025 pertaining to the dermatological health and care of Muslim patients. We first discuss several key religious and cultural topics that can influence Muslim patients’ perspectives on and participation with dermatological care, including views on contraception, modesty, divine will, and use of traditional medicines. Next, we summarize some specific religious and cultural prohibitions and observances than can affect dermatologic care, including tenets surrounding medications that contain animal products and the practice of fasting during the holy month of Ramadan. Lastly, we outline some key dermatoses associated with specific religious practices dermatologists should be aware of to enhance diagnostic accuracy and ensure timely, appropriate care. Importantly, we outline some key recommended clinical practices for providing evidence-based, culturally responsive dermatological care that respects patients’ privacy, dignity, and spiritual values. Culturally competent dermatologic practice requires that clinicians understand health conditions and behaviors associated with religious and cultural practices and can employ clinical communication strategies that respect and incorporate patients’ personal preferences. Enhanced awareness of the unique cultural and religious factors affecting dermatologic health in Muslim communities can help dermatologists foster trust and provide more effective, patient-centered care.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"503 - 514"},"PeriodicalIF":8.8,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01020-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis","authors":"César Ferreira,&nbsp;Tiago Torres","doi":"10.1007/s40257-026-01019-0","DOIUrl":"10.1007/s40257-026-01019-0","url":null,"abstract":"<div><p>Psoriasis is a chronic, immune-mediated inflammatory disease with substantial impact on quality of life. While biologic therapies targeting interleukin (IL)-23 and IL-17 have set new efficacy and safety benchmarks, currently available oral agents offer limited potency or tolerability. There remains an unmet need for an oral therapy that combines the convenience of oral administration with the efficacy and safety of biologic agents. Icotrokinra, a first-in-class, orally administered macrocyclic peptide that selectively targets the IL-23 receptor (IL-23R), has been evaluated across phase 2 and 3 clinical trials in moderate-to-severe plaque psoriasis. This review aimed to provide an overview of icotrokinra in psoriasis, based on a literature search up to December 2025 using PubMed and supplemented by conference abstracts, industry communications, and ClinicalTrials.gov. In the phase 2b FRONTIER-1 trial, icotrokinra demonstrated a clear dose–response relationship, with sustained efficacy through 52 weeks in the FRONTIER-2 long-term extension. In the pivotal phase 3 ICONIC-ADVANCE-1 and ICONIC-ADVANCE-2 studies, icotrokinra was superior to placebo in achieving the primary endpoints of Investigator’s Global Assessment (IGA) score 0/1 (clear or almost clear skin) and ≥ 90% improvement in the Psoriasis Area and Severity Index (PASI90) at week 16, and demonstrated greater efficacy than deucravacitinib at week 24, while maintaining a favorable safety profile. Long-term results from ICONIC-LEAD confirmed durable efficacy through 52 weeks, while ICONIC-TOTAL demonstrated consistent outcomes in scalp, genital, and palmoplantar psoriasis. Adverse events were mostly mild and comparable to placebo, with no new safety signals or pharmacokinetic concerns. Icotrokinra is the first oral IL-23R antagonist to achieve high and durable levels of skin clearance with a favorable safety profile, highlighting the potential of selective oral IL-23R blockade with minimal off-target or drug–drug interaction potential, thereby overcoming key limitations of oral small molecules.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 3","pages":"479 - 492"},"PeriodicalIF":8.8,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-026-01019-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Systemic Treatments for Atopic Dermatitis in the Head-and-Neck-Area: A Systematic Review and Meta-analysis","authors":"Elizabeth Munkebjerg Stevens,&nbsp;Kirstine Vester-Glowinski,&nbsp;Lone Skov,&nbsp;Mette Gyldenløve,&nbsp;Nikolai Loft","doi":"10.1007/s40257-026-01013-6","DOIUrl":"10.1007/s40257-026-01013-6","url":null,"abstract":"<div><h3>Background</h3><p>Involvement of the head-and-neck area in atopic dermatitis (AD) is common, associated with reduced quality of life, and suggested as an independent criterion for moderate-to-severe AD. The effectiveness of systemic therapies for AD specifically in the head-and-neck area remains underexplored.</p><h3>Objective</h3><p>The objective was to evaluate the effectiveness of approved anti-inflammatory systemic therapies for AD in the head-and-neck area through a systematic review and meta-analysis.</p><h3>Methods</h3><p>We conducted a systematic literature search in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) indentifying studies reporting response to systemic anti-inflammatory therapies for AD in the head-and-neck region. Searches were conducted in the databases PubMed, EMBASE, and Web of Science from inception through June 2025. The primary outcomes were mean percentage change of Eczema Area and Severity Index (EASI) for the head-and-neck region (EASI-HN), and proportion of patients achieving 75% improvement of EASI for the head-and-neck region (EASI75-HN). Meta-analyses were performed where data permitted.</p><h3>Results</h3><p>In total, 22 publications, encompassing 32 unique studies and 11,372 patients in total, met the inclusion criteria. Of the 22 included publications, eight were post hoc analyses of randomized controlled trials (RCTs), and 14 were observational real-world studies. Across studies, the mean reductions of EASI-HN after 16 weeks of treatment ranged from 59% (dupilumab 300 mg every 2 weeks (Q2W) without topical therapy) and 67% (lebrikizumab 250 mg Q2W without topical therapy) to 80% (upadacitinib 30 mg once daily (QD) without topical therapy) and 85% (dupilumab 300 mg Q2W with concomitant topical therapy). EASI75-HN after 16 weeks of treatment ranged from 20% (baricitinib 2 and 4 mg QD) to 66% (upadacitinib 30 mg QD). Evidence for the conventional systemic therapies, cyclosporine and methotrexate, was limited and not readily comparable to the other treatments.</p><h3>Conclusions</h3><p>In this systematic review, biologics and Janus kinase inhibitors (JAKis) were effective in treating AD in the head-and-neck region, achieving treatment responses comparable to those observed in other body regions. Further research providing direct comparison between therapies are warranted.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"27 2","pages":"277 - 295"},"PeriodicalIF":8.8,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}